Drug

AMG623 peptibody clinical trials

Also written Blisibimod, A-623 and AMG 623.

studies test it: 11
open now: 0
in phase 3: 6
first study started: 2004

How studies write it

Studies that test it under each name

Development codes

A-623: 3
AMG 623: 2

Other names

Blisibimod: 7

Studies by the year they started

11 studies that test it; most in 2013 (2)

Studies that test AMG623 peptibody, by start year
Year	Studies
2004	1
2005	1
2010	1
2011	1
2013	2
2014	2
2015	2
2016	1

By phase

A phase 1/2 study counts in both.

Phase 1: 2
Phase 2: 5
Phase 3: 6

What it is tested for

Each study’s main condition, where its own words name it.

Lupus Erythematosus, Systemic: 5
Glomerulonephritis, IGA: 2
Nephritis: 2
Granulomatosis with Polyangiitis: 1
Purpura, Thrombocytopenic, Idiopathic: 1

Who runs them

Industry 11 · Other 0

Anthera Pharmaceuticals (9) · Amgen (2)

Studies

Open first, then newest update. How each study uses AMG623 peptibody is read from its arms, and is right about nine times in ten.

Testing it · 11

BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous AdministrationCompletedPhase 2/3Anthera PharmaceuticalsNCT02062684Written as Blisibimod
CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without NephritisTerminatedPhase 3Anthera PharmaceuticalsNCT02514967Written as Blisibimod
CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus ErythematosusCompletedPhase 3Anthera PharmaceuticalsNCT01395745Written as blisibimod
CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without NephritisWithdrawnPhase 3Anthera PharmaceuticalsNCT02074020Written as Blisibimod
BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel VasculitisWithdrawnPhase 2Anthera PharmaceuticalsNCT01598857Written as Blisibimod
BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA NephropathyWithdrawnPhase 3Anthera PharmaceuticalsNCT02052219Written as Blisibimod
MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITPWithdrawnPhase 2/3Anthera PharmaceuticalsNCT01609452Written as Blisibimod
A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus ErythematosusCompletedPhase 1AmgenNCT02443506Written as AMG 623
A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus ErythematosusCompletedPhase 1AmgenNCT02411136Written as AMG 623
PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus ErythematosusCompletedPhase 2Anthera PharmaceuticalsNCT01162681Written as A-623
A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321CompletedPhase 2Anthera PharmaceuticalsNCT01305746Written as A-623